The difference between the formal and the functional dose: The case of the patient on thioridazine and fluvoxamine

Journal of Psychiatric Practice

Volumn 11, Issue 3, 2005, Pages 192-196

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A; ERYTHROMYCIN; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PAROXETINE; THIORIDAZINE;

ADULT; AUTOPSY; CASE REPORT; CAUSE OF DEATH; DEPRESSION; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG FATALITY; DRUG INFORMATION; DRUG INTOXICATION; DRUG POTENTIATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SUICIDE; TORSADE DES POINTES;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATAL OUTCOME; FEMALE; FLUVOXAMINE; HUMANS; MENTAL RETARDATION; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; THIORIDAZINE;

EID: 19944376876     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200505000-00006     Document Type: Review

References (35)

1. Preskorn SH. Defining "is." J Pract Psychiatry Behav Health 1999;5:224-8.
2. Preskorn SH. The stages of drug development and the human genome project: Drug discovery. J Psychiatr Pract 2000;6:341-4.
3. The rationale for and clinical implications of dose-response curves. Series of columns published in the Journal of Psychiatric Practice (www.preskorn.com/column3.html).
4. Preskorn SH. What happened to Tommy? J Pract Psychiatry Behav Health 1998;4:363-7.
5. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psychiatr Pract 2004;10:177-81.
6. Preskorn SH. Antipsychotic drug development in the prehuman-genome era: A full circle. J Psychiatr Pract 2001;7:209-13.
7. Hartigan-Go K, Bateman DN, Nyberg G, et al. Pharmacodynamics and drug action: Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543-53.
8. Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 1999;288:1261-8.
9. Kelly HG, Fay JE, Laverty SG. Thioridazine hydrochloride (Mellaril): Its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963;89:546-54.
10. Huston JR, Bell GE. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram. JAMA 1966;198:134-8.
11. Schoonmaker FW, Osteen RT, Greenfield JC, Jr. Thioridazine (Mellaril)-induced ventricular tachycardia controlled with an artificial pacemaker. Ann Intern Med 1966;65:1076-8.
12. Fowler NO, McCall D, Chou TC, et al. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37:223-30.
13. Kemper AJ, Dunlap R, Pietro DA. Thioridazine-induced torsade de pointes: Successful therapy with isoproterenol. JAMA 1983;249:2931-4.
14. Quieffin J, Brochet E, Gamerman G, et al. Ventricular arrhythmia following thioridazine poisoning. Ann Cardiol Angeiol (Paris) 1991;40:199-201.
15. Hulisz DT, Dasa SL, Black LD, et al. Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 1994;14:239-45.
16. Reilly JG, Avis SA, Ferrier IN, et al. Thioridazine and sudden death in psychiatric in-patients. Br J Psychiatry 2002;180:515-22.
17. Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 1999;19:494-9.
18. Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, et al., eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000: 563-77.
19. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(Suppl 1):1-21.
20. Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psychiatr Pract 2002;8:233-8.
21. Preskorn SH. Clinical pharmacology case conference: A suicide attempt? J Psychiatr Pract 2002;8:306-10.
22. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy (letter). JAMA 1997;277:682.
23. Preskorn SH. Drug-drug interactions: Proof of relevance (Part I). J Psychiatr Pract 2005;11:116-22.
24. The case studies section. Series of columns published in the Journal of Psychiatric Practice (can be accessed at www .preskorn.com/column1.html).
25. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-8.
26. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-36.
27. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
28. Eap CB, Guentert TW, Schaublin-Loidl M, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996;59:322-31.
29. Daniel WA, Syrek M, Haduch A. Effects of selective cytochrome P-450 inhibitors on the metabolism of thioridazine: In vitro studies. Pol J Pharmacol 1999;51:435-42.
30. Daniel WA, Syrek M, Haduch A. The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. Eur Neuropsychopharmacol 2002;12:371-7.
31. Berecz R, de la Rubia A, Dorado P, et al. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003;59:45-50.
32. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9.
33. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clin Pharmacokinet 2002;41:453-70.
34. Spigset O, Axelsson S, Norstrom A, et al. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001;57:653-8.
35. Gerstenberg G, Aoshima T, Fukasawa T, et al. Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit 2003;25:463-8.